| Market Cap | 3.05M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -10.61M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -69.00% |
| Sales | 80.38M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -98.00% |
| Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -100.00% |
| Recommedations | - | Quick Ratio | 0.59 | Shares Outstanding | 33.93M | 52W Low Chg | - |
| Insider Own | - | ROA | -0.50% | Shares Float | 11.80M | Beta | 0.86 |
| Inst Own | 0.00% | ROE | -8.78% | Shares Shorted/Prior | 12.62K/4.70K | Price | 0.00040 |
| Gross Margin | 18.09% | Profit Margin | -13.18% | Avg. Volume | 6,216 | Target Price | - |
| Oper. Margin | -2.77% | Earnings Date | - | Volume | 1,085 | Change | 0.00% |
Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Pointe-Claire, Canada.
